AndreaBozzo/ceres-open-data-index huggingface dataset:
Pre-dialysis clinic attendance improves quality of life among hemodialysis patients

Background
          Although previous research has demonstrated that referral to pre-dialysis clinics is associated with favourable objective outcomes, the benefit of a pre-dialysis clinic from the perspective of patient-perceived subjective outcomes, such as quality of life (QOL), is less well defined.
        
        
          Methods
          A retrospective incident cohort study was conducted to determine if pre-dialysis clinic attendance was a predictor of better QOL scores measured within the first six months of hemodialysis (HD) initiation. Inclusion criteria were HD initiation from January 1 1998 to January 1 2000, diagnosis of chronic renal failure, and completion of the QOL questionnaire within six months of HD initiation. Patients receiving HD for less than four weeks were excluded. An incident cohort of 120 dialysis patients was identified, including 74 patients who attended at least one pre-dialysis clinic and 46 patients who did not. QOL was measured using the SF 36-Item Health Survey. Independent variables included age, sex, diabetes, pre-dialysis clinic attendance and length of attendance, history of ischemic heart disease, stroke, peripheral vascular disease, heart failure, malignancy, and chronic lung disease, residual creatinine clearance at dialysis initiation, and kt/v, albumin and hemoglobin at the time of QOL assessment. Bivariate and multivariate linear regression analyses were used to identify predictors of QOL scores.
        
        
          Results
          Multivariate analysis suggested that pre-dialysis clinic attendance was an independent predictor of higher QOL scores in four of eight health domains (physical function, p < 0.01; emotional role limitation, p = 0.01; social function, p = 0.01; and general health, p = 0.03), even after statistical adjustment for age, sex, residual renal function, kt/v, albumin, and co-morbid disease. Pre-dialysis clinic attendance was also an independent predictor of the physical component summary score (p = 0.03).
        
        
          Conclusions
          We conclude that pre-dialysis clinic attendance favourably influences patient-perceived quality of life within six months of dialysis initiation.
Working With the Correctional System and Incarcerated Parents

This Child Welfare Information Gateway Podcast is available on Apple Podcasts
  
  

, GooglePlay
  
  

, Spotify
  
  

, Stitcher
  
  

, SoundCloud
  
  

, and the Child Welfare Information Gateway
  
  

 website. Subscribe to receive new episodes as they are released.

Metadata-only record linking to the original dataset. Open original dataset below.
Compound 526828: 11-Hydroxy-palmitic acid, methyl ester, tBDMS ether

Chemical compound data from PubChem database. IUPAC Name: methyl 11-[tert-butyl(dimethyl)silyl]oxyhexadecanoate. Molecular Formula: C23H48O3Si. Molecular Weight: 400.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E401142-T1: [Translated] STRAP TREATMENT SYSTEM FOR RIGHTENING METAL STRAPS

A strip treatment line in which downstream of the processing roll stand for stainless steel strip, first and second tension rolls are provided to directly form a prestretching zone A for elastic or elastoplastic stretching of the strip following the dressing mill stand and for providing an afterstretching zone with elastoplastic or plastic stretching of the strip.
National Survey of Substance Abuse Treatment Services (N-SSATS-2013)

<p>The National Survey of Substance Abuse Treatment Services (N-SSATS) is designed to collect information from all facilities in the United States, both public and private, that provide substance abuse treatment. N-SSATS provides the mechanism for quantifying the dynamic character and composition of the United States substance abuse treatment delivery system. The objectives of N-SSATS are to collect multipurpose data that can be used to assist the Substance Abuse and Mental Health Services Administration (SAMHSA) and state and local governments in assessing the nature and extent of services provided and in forecasting treatment resource requirements, to update SAMHSA's Inventory of Behavioral Health Services (I-BHS), to analyze general treatment services trends, and to generate the online Substance Abuse Treatment Facility Locator <a href="http://findtreatment.samhsa.gov">http://findtreatment.samhsa.gov</a>, as well as the National Directory of Drug and Alcohol Abuse Treatment Programs.</p>
<p>Data are collected on topics including facility operation, services offered (assessment, testing, transitional, ancillary, and pharmacotherapies), detoxification, primary focus (substance abuse, mental health, both, general health, and other), Opioid Treatment Programs and medications dispensed/prescribed, counseling and therapeutic approaches, standard operating procedures, special programs/groups offered, languages in which treatment is provided, type of treatment provided (hospital inpatient, residential, outpatient), number of clients (by service, total, and under age 18), number of beds, types of payment accepted, sliding fee scale, and facility accreditation and licensure/certification.<br />
This study has 1 Data Set.</p>
Monthly Caseworker Visit (funds)

Program Description:

Title IV-B, subpart 2 of the Social Security Act sets aside funding for formula grants to help states improve the quality of caseworker visits with children in foster care, with an emphasis on improving caseworker decision-making on the safety, permanency, and well-being of children in foster children and caseworker recruitment, retention and training.

Budget Information

Standards for Caseworker Visits

The law also sets performance standards for caseworker visits and requires states to submit annual data on the percentage of children in foster care receiving monthly caseworker visits and the percentage of such visits occurring in the residence of the child.  Since FY 2015 states have been required to ensure the total number of monthly caseworker visits is not less than 95 percent of the total visits that would be made if each child in foster care were visited once per month.  In addition, at least 50 percent of the total number of monthly visits made by caseworkers to children in foster care must occur in the child’s residence.

States that do not meet the performance targets are subject to reductions in the rate of Federal Financial Participation (FFP) under the title IV-B, subpart 1 program (Stephanie Tubbs Jones Child Welfare Services Program).  Reductions in FFP may range from one to five percentage points for each performance measure, depending on the extent to which the expected level was not achieved.  States may continue to receive their full federal grant award but must provide a higher state match to receive the full funding.

Metadata-only record linking to the original dataset. Open original dataset below.
Compound 530378: (3-(3-Methoxy-4-[(trimethylsilyl)oxy]phenyl)propoxy)(trimethyl)silane

Chemical compound data from PubChem database. IUPAC Name: 3-(3-methoxy-4-trimethylsilyloxyphenyl)propoxy-trimethylsilane. Molecular Formula: C16H30O3Si2. Molecular Weight: 326.58. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528412: Flavone, 3,5,7-trihydroxy, bis-TMS

Chemical compound data from PubChem database. IUPAC Name: 3-hydroxy-2-phenyl-5,7-bis(trimethylsilyloxy)chromen-4-one. Molecular Formula: C21H26O5Si2. Molecular Weight: 414.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
MedlinePlus Connect for Electronic Health Record (EHR) Systems - Web Application

<p>A Web application that allows patient portals and electronic health record (EHR) systems to use existing code sets to link to relevant, authoritative health information from MedlinePlus.gov.  Matches ICD-9-CM or SNOMED CT codes to related MedlinePlus consumer health information, LOINC codes to information on lab tests, and also matches NDC, RXCUI or text strings to patient medication information.</p>
Patent AT-E399795-T1: [Translated] METHOD FOR PRODUCING IMPROVED DEXTRAN-HEMOGLOBIN CONJUGATES

An hemoglobin (Hb)-Dextran (Dx) conjugate having a molecular weight between 50 kd and 500 kD provides a blood substitute that results in acceptable erythrocyte sedimentation rate (ESR) and excretion rate (EXC) values. DxHb conjugates of the invention can be used for a variety of purposes as an alternative to blood.
Mesenchymally-derived Insulin-like growth factor 1 provides a paracrine stimulus for trophoblast migration

Background
          Trophoblast migration into maternal decidua is essential for normal pregnancy. It occurs in a defined time window, is spatially highly restricted, and is aberrant in some pathological pregnancies, but the control mechanisms are as yet ill-defined. At the periphery of the placenta, chorionic villi make contact with decidua to form specialised anchoring sites that feed interstitially migrating cytotrophoblast into the placental bed.
        
        
          Results
          Explants of first trimester mesenchymal villi on collagen type I developed cytotrophoblast outgrowths from the villous tips. However, in medium changed daily, cells did not progress to a migratory phenotype, remaining instead as a contiguous multi-layered sheet. This suggested the need for another migration stimulus. To test the possibility that this might arise from mesenchymal cells, serum-free conditioned medium from first trimester placental fibroblasts was added to explant cultures. Cytotrophoblasts were stimulated to migrate in streams across the gel. Affinity depletion of Insulin-like growth factor from fibroblast medium reduced streaming activity, while the addition of exogenous IGF-I (10 ng/ml) to serum-free medium produced a streaming phenotype. IGF receptor type 1 (IGFR1) was present on cells in the columns, and streaming could be inhibited by antibody to this receptor. IGF-II and activin, known stimulators of cytotrophoblast migration, were also active in this model.
        
        
          Conclusions
          These data suggest a paracrine interaction between villous mesenchyme and the cytotrophoblast in anchoring sites that stimulates trophoblast infiltration of decidua. Such a signal would be self-limiting since it diminishes with distance from the placenta. This is a novel mechanism in placental development.
Miami - Fort Lauderdale Div: Drug-Related Emergency Department Visits, 2008-2011 - Illicits (excluding alcohol)

Excel file with estimates, rates, relative standard errors, trends and confidence intervals for all drug-related emergency department (ED) visits involving illicit drugs for the Miami metropolitan area, Fort Lauderdale division, covering 2008-2011. These visits involve the use of drugs that have limited or no therapeutic value and are generally illegal if taken without a prescription. It also includes visits involving the inhalation of substances for their psychoactive properties (e.g., sniffing model airplane glue).
Ergocalciferol

Ergocalciferol, also known as Vitamin D2, is a prescription medication used to treat vitamin D deficiency. It comes as a liquid-filled oral capsule containing 50,000 IU (1.25 mg) of ergocalciferol, manufactured by Bionpharma Inc. This helps the body absorb calcium and maintain healthy bones. This information was generated using AI and is provided for informational and research purposes only.
Tolterodine tartrate

Tolterodine Tartrate is a prescription medication used to treat symptoms of overactive bladder, such as frequent urination and urgency. It comes as extended-release capsules in 2mg and 4mg strengths, taken orally once daily. Manufactured by Camber Pharmaceuticals, Inc., this generic drug is an anticholinergic that helps relax bladder muscles. This information was generated using AI and is provided for informational and research purposes only.
Compound 529622: Calacorene oxide

Chemical compound data from PubChem database. IUPAC Name: 5,7b-dimethyl-3-propan-2-yl-2,3-dihydro-1aH-naphtho[1,2-b]oxirene. Molecular Formula: C15H20O. Molecular Weight: 216.32. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
New Jersey 2016 Potential Areas for Addressing Service Gaps for Opioid Treatment

The purpose of the medication-assisted treatment (MAT) facility maps is to identify areas on a state-by-state basis that may be potentially underserved by existing treatment facilities. The maps are created with a methodology that seeks to include the highest potential need areas from individual counties so that county-level stakeholders are also informed. The maps are meant to be used as a tool for policy makers to determine potentially underserved areas—not as a definitive representation of these areas.
Possible association of β

Background
          The involvement of β2-adrenergic receptor (ADRB2) and β3-adrenergic receptor (ADRB3) in both adipocyte lipolysis and thermogenic activity suggests that polymorphisms in the encoding genes might be linked with interindividual variation in obesity, an important risk factor for postmenopausal breast cancer. In order to examine the hypothesis that genetic variations in ADRB2 and ADRB3 represent interindividual susceptibility factors for obesity and breast cancer, we conducted a hospital-based, case-control study in the Aichi Cancer Center, Japan.
        
        
          Methods
          A self-administered questionnaire was given to 200 breast cancer patients and 182 control individuals, and pertinent information on lifestyle, family history and reproduction was collected. ADRB2 and ADRB3 genotypes were determined by polymerase chain reaction (PCR) restriction fragment length polymorphism assessment.
        
        
          Results
          Twenty-five (12.4%) breast cancer patients and 32 (17.6%) control individuals were found to bear a glutamic acid (Glu) allele for the ADRB2 gene (odds ratio [OR] 0.67, 95% confidence interval [CI] 0.38-1.18), and 60 (30.0%) breast cancer patients and 61 (33.5%) control individuals were found to bear an Arg allele for the ADRB3 gene (OR 0.85, 95% CI 0.55-1.31). A significantly lower risk was observed in those who carried the Glu ADRB2 allele and who reported first childbirth when they were younger than 25 years (OR 0.35; 95% CI 0.13-0.99).
        
        
          Conclusion
          A potential association may exist between risk of breast cancer and polymorphisms in the ADRB2 and ADRB3 genes; further studies in larger samples and/or in different ethnic groups are warranted to investigate this potential association.
Patent AT-E401117-T1: [Translated] CERAMIC FILTER FOR EXHAUST GAS CLEANING

A ceramic filter assembly integrated by adhering together a plurality of columnar honeycomb filters made of a porous ceramic sintered material with a ceramic sealing material layer and having a generally elliptical cross sectional shape when cut parallel to end faces of the plurality of honeycomb filters, the ceramic filter assembly characterized in that when a hypothetical first straight line intersects the generally elliptical contour at two points in which the distance therebetween is maximum and a hypothetical second straight line orthogonal to the first straight line intersects the generally elliptical contour at two points in which the distance therebetween is minimum, the number of sealing material layers the first straight line of the assembly traverses is less than or equal to the number of sealing material layers the second straight line traverses.
Compound 525086: [10,13-dimethyl-17-(6-methylheptan-2-yl)-3-trimethylsilyloxy-6,7,8,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-7-yl]oxy-trimethylsilane

Chemical compound data from PubChem database. IUPAC Name: [10,13-dimethyl-17-(6-methylheptan-2-yl)-3-trimethylsilyloxy-6,7,8,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-7-yl]oxy-trimethylsilane. Molecular Formula: C33H60O2Si2. Molecular Weight: 545.0. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Program Instruction (PI-14-04)

This Program Instruction (PI) provides instruction to Tribes on the June 30, 2014 Submission of: (1) the Child and Family Services Plan (CFSP) Final Report for fiscal years (FYs) 2010-2014; (2) the Child and Family Services Plan for FYs 2015-2019 for the Stephanie Tubbs Jones Child Welfare Services and Promoting Safe and Stable Families (PSSF) Programs, the Chafee Foster Care Independence Program (CFCIP) and the Education and Training Vouchers (ETV) Program; and (3) the CFS-101, Part I, Annual Budget Request, Part II, Annual Summary of Child and Family Services, and Part III, Annual Expenditure Report—Title IV-B, Subparts 1 and 2, CFCIP and ETV, as applicable.

PI-14-04 (PDF)

Fiscal Year 2014 Allotment Title IV-B, Subpart 1 Stephanie Tubbs Jones Child Welfare Services
Fiscal Year 2014 Allotment Title IV-B, Subpart 2 - Promoting Safe and Stable Families
Fiscal Year 2014 Chafee Foster Care Independence Program and Education and Training Voucher Program

CFS-101 Part I: Annual Budget Request for Title IV-B, Subparts 1 and 2, CAPTA, Chafee Foster Care Independence (CFCIP) and Education and Training Voucher (ETV) Program Instructions
CFS-101 Part I: Annual Budget Request for Title IV-B, Subparts 1 and 2, CAPTA, Chafee Foster Care Independence (CFCIP) and Education and Training Voucher (ETV) Program Form (Excel (XLSX) - 15 KB)
CFS-101, Part II: Annual Summary of Child and Family Services Instructions
CFS-101, Part II: Annual Summary of Child and Family Services Form (Excel (XLSX) - 15 KB)
CFS-101, Part III: Annual Expenditures for Title IV-B, Subparts 1 and 2, CAPTA, Chafee Foster Care Independence (CFCIP) and Education and Training Voucher (ETV) Instructions
CFS-101, Part III: Annual Expenditures for Title IV-B, Subparts 1 and 2, CAPTA, Chafee Foster Care Independence (CFCIP) and Education and Training Voucher (ETV) Form (Excel (XLSX) - 14 KB)

Assurances and Certifications

Children’s Bureau Regional Program Managers

Current Variances in the Title IV-B Provisions of Law and Regulations

Certification of Tribal Population Under Age 21 (Word (DOCX) - 14 KB)

Training Plan Template (optional) (Word (DOCX) - 30 KB)

Tribal CFSP Template (optional) (Word (DOCX) - 43 KB)

Metadata-only record linking to the original dataset. Open original dataset below.
Medicaid Coverage Of Cessation Treatments And Barriers To Treatments

2008-2024. American Lung Association. Cessation Coverage.  Medicaid data compiled by the Centers for Disease Control and Prevention’s Office on Smoking and Health were obtained from the State Tobacco Cessation Coverage Database, developed and administered by the American Lung Association.  Data from 2008-2012 are reported on an annual basis; beginning in 2013 data are reported on a quarterly basis.  Data include state-level information on Medicaid coverage of approved medications by the Food and Drug Administration (FDA) for tobacco cessation treatment; types of counseling recommended by the Public Health Service (PHS) and barriers to accessing cessation treatment. Note: Section 2502 of the Patient Protection and Affordable Care Act requires all state Medicaid programs to cover all FDA-approved tobacco cessation medications as of January 1, 2014. However, states are currently in the process of modifying their coverage to come into compliance with this requirement. Data in the STATE System on Medicaid coverage of tobacco cessation medications reflect evidence of coverage that is found in documentable sources, and may not yet reflect medications covered under this requirement.
Patent AT-E399972-T1: [Translated] CASE COLLECTION DEVICE FOR A LINKLESS AMMUNITION

Shell catching device has conveyor (1) for conveying ammunition and ammunition feeder (7) of weapon, which has weapon-side extractor (4), ejection pipe (6) and shell dampener (8) which is functionally connected to ejection pipe. The shell (2) or ammunition ejected with high speed through ejection pipe to shell catching spring (21) which is arranged in between the ejection pipe and shell dampener. During the impingement of shell or ammunition on shell catching spring, the shell or ammunition acts upon the shell dampener and the catching energy is reduced. An independent claim is also included for the cartridge holder.
2022-2023 NSDUH: State Estimates of Substance Use and Mental Health

Find state-level estimates for 38 measures of substance use and mental health from the 2022-2023 National Surveys on Drug Use and Health (NSDUH). These estimates are based on small area estimation (SAE) methods in which state-level NSDUH data are combined with other data from smaller geographies. The combined data are used to create modeled state estimates of the civilian, noninstitutionalized population ages 12 and older, both overall and by age group.Along with the estimates, the collection includes: tables that allow statistical comparisons between estimates (across time and geography), an overview of the estimation methodology, and a review of other state-level substance use and mental health data sources.The data are available as tables by measure or by state in a variety of file formats.
2025 General Payment Data

All general (non-research, non-ownership related) payments from the 2025 program year [January 1 – December 31, 2025] <p><strong>NOTE:</strong> This is a very large file and, depending on your network characteristics and software, may take a long time to download or fail to download. Additionally, the number of rows in the file may be larger than the maximum rows your version of <a href="https://support.microsoft.com/en-us/office/excel-specifications-and-limits-1672b34d-7043-467e-8e27-269d656771c3">Microsoft Excel</a> supports. If you can't download the file, we recommend engaging your IT support staff. If you are able to download the file but are unable to open it in MS Excel or get a message that the data has been truncated, we recommend trying alternative programs such as MS Access, Universal Viewer, Editpad or any other software your organization has available for large datasets.</p>
Patent AT-E399584-T1: [Translated] LIQUID SEPARATION DEVICE

The present invention relates to a fluid separation device (10) for separating fluid, oil and oil spray from a gas. This fluid separation device (10) comprises a base carrier (21) in which fluid separator elements (20) in the form of flow-through tubes with worm-like segments (23) arranged therein, are integrated. The worm-like segments (23) at the same time form spiral flow paths (25) for the gas. They have a maximal length of half a pitch of the worm-like segment (23) so that the base carrier (21) together with the associated fluid separator elements (20) may be formed as one piece. Several base carriers may be arranged one after the other in a manner such that individual fluid separator elements of various base carriers form a common flow path for the gas.
Patent AT-E401075-T1: [Translated] MEDICINAL PRODUCT CONTAINING CYTISINE

The invention relates to a cytisine containing solid dosage form for oral administration. It helps achieve an even distribution of the active substance throughout the tablet mass. The resulting tablets possess high mechanical strength, high solubility of cytisine and good disintegration. This is achieved through appropriate lactose and microcrystal cellulose ratios and contents of the cytisine tablets.